Skip to main content

Table 2 Comparisons of clinical and laboratory parameters in the two groups

From: Correlation between anti-thyroid peroxidase antibody levels and diffuse thyroid uptake of 18F-fluorodeoxyglucose in Hashimoto’s thyroiditis: a retrospective study

 

Group 1: Patients with diffuse uptake

Group 2: Patients without diffuse uptake

p

n (female)

13 (10)

5 (3)

0.583

Serum TSH

Median (minimum-maximum)

22.43 (3.24–266.1)

11.01 (0.033–12.27)

0.143

Serum TSH

(only patients without replacement therapy)

Median (minimum-maximum)

8.45 (3.24–266.1)

8.20 (0.03–11.23)

0.414

Serum free T3

Median (minimum-maximum)

2.20 (1.16–3.21)

2.39 (0.89–3.12)

0.921

Serum free T4

Median (minimum-maximum)

0.93 (0.19–1.32)

1.11 (0.96–1.56)

<  0.05

Serum free T4

(only patients without replacement therapy)

Median (minimum-maximum)

0.94 (0.19–1.32)

1.10 (0.96–1.23)

0.247

Serum thyroglobulin

Median (minimum-maximum)

1.465 (0.08–175.0)

3.435 (2.94–3.93)

0.533

Tg-Ab titer

Median (minimum-maximum)

1360 (122–4000)

18 (16–465)

<  0.01

TPO-Ab titer

Median (minimum-maximum)

184 (16–600)

16 (8–22)

<  0.01

  1. TSH thyroid stimulating hormone, Tg-Ab anti-thyroglobulin antibody, TPO-Ab anti-thyroid peroxidase antibody